Verano Repudiates Transaction to Acquire Goodness Growth Holdings
MINNEAPOLIS, Minn. and VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. (CSE: GDNS) (OTCQX: GDNSF)...
Month: October 2022
Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox Vaccine
Switzerland has ordered 100,000 doses of smallpox and monkeypox vaccine with deliveries starting imminentlyBavarian Nordic will seek regulatory approval of...
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
- Enzo Life Sciences reports revenue of $32.6 million and 8% growth in FY 2022, net of FX - Company...
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease...
Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer
Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1Approximately...
Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference
VANCOUVER, British Columbia, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Myovant Sciences to Host Second Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m.
BASEL, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), today announced it will host a webcast and conference...
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”),...
Significant increase of the turnover as of September 2022 compared with last year third quarter
Press Release Ecully, October 14, 2022 – 8 am Nine-month turnover of €5.4 million, up 82% Sales double in...
Pierce County Alliance Celebrates 50th Anniversary Serving the Pacific Northwest in Substance Abuse Treatment
TACOMA, Wash., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Pierce County Alliance (PCA), founded in 1972, will celebrate its 50th Anniversary...
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods®Technology Notice of Patent Allowance...
Enliven Therapeutics and Imara Announce Merger Agreement
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to...
Kane Biotech to Present at Symposium on Advanced Wound Care Fall Forum
Company presenting technologies for improving patient outcomes in wound careWINNIPEG, Manitoba, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc....
Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow
TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device...
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
Dosing in KT-474 Phase 1 HS and AD patient cohort (Part C) complete KT-413 and KT-333 continuing in Phase 1...
Seer to Report Third Quarter 2022 Financial Results on November 8, 2022
REDWOOD CITY, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive...
ERYTECH Announces Receipt of Nasdaq Notice
ERYTECH Announces Receipt of Nasdaq Notice Cambridge, MA (U.S.) and Lyon (France), October 13, 2022 – ERYTECH Pharma (Nasdaq &...
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics,...
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
Highlights include data from non-clinical and microbiology programs and real-world patient use BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek...
IO Biotech Announces Appointment of New Chief Financial Officer
NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...